SUNDAY, 7 JUNE 2015


10:00 – 10:30 PT 1 – FAES FARMA and the Menarini Group, Pro & Con Arena

Updosing or combination of antihistamines? What is the better way of treating chronic urticaria?
Speakers: Marcus Maurer, Germany and Carsten Bindslev-Jensen, Denmark

 

10:30 – 12:00 CSS 1 – MEDA Pharma GmbH & Co. KG, Hall A

A new frontier in allergic rhinitis management: meeting the challenge
Chair: Joaquim Mullol, Spain

– Introduction (Joaquim Mullol, Spain)
– Guideline challenge: time for the next generation? (Jean Bousquet, France)
– MP29-02: Meeting the guideline challenge (Claus Bachert, Belgium)
– Effectiveness and communication in real-life: essential pieces of the puzzle (David Price,UK)
– Discussion (Jean Bousquet, France)

 

13:30 – 15:00 CSS 2 – Novartis Pharmaceuticals, Room 117

Back to the future: the IgE journey in asthma, chronic spontaneous urticaria and beyond
Chairs: Stephen Holgate, UK and Ana Giménez-Arnau, Spain

– Chairs’ Welcome (Stephen Holgate, UK and Ana Giménez-Arnau, Spain)
– The IgE journey in asthma, chronic spontaneous urticaria and beyond (Eugene Bleecker, USA)
– Let’s talk patients – Case-study based discussion (Thomas Casale, USA and Ana Giménez-Arnau, Spain)
– Chairs’ summary and close (Stephen Holgate, UK and Ana Giménez-Arnau, Spain)

webcast_button2

 

 

 

15:00 – 15:30 PT 2 – Airsonett AB, Pro & Con Arena

Health Economics: Temperature Laminar Airflow (TLA) from controlled trial to clinical practice
Speaker: John O. Warner, UK

 

15:30 – 17:00 CSS 3 – Stallergenes, Hall A

Thinking differently about house dust mite respiratory allergy
Chairs: Joaquin Sastre, Spain

– The hidden face of the HDM allergy patient (Carmen Vidal, Spain)
– What can allergen immunotherapy bring to the patient with HDM allergy today? (Giovanni Passalacqua, Italy)
– Crossing new frontiers in HDM allergen immunotherapy (Pascal Demoly, France)

webcast_button2

 

 

 

17:30 – 19:00 SAT 1 – FAES Farma and the Menarini Group, Room 111

New frontiers for new H1-antihistamines: what’s different from the past?
Chairs: G. Walter Canonica, Italy and Tomás Chivato, Spain

– Past, present and future of antihistamines (Martin Church, UK)
– Bilastine: a high-flying antihistamine (Ralph Mösges, Germany)
– A new frontier in new indications: the pediatric challenge (Zoltan Novak, Hungary)

 

17:30 – 19:00 SAT 2 – Shire International GmbH, Room 113

Working to Improve Quality of Life for Patients with Hereditary Angioedema (HAE)
Chair: Marcus Maurer, Germany

– Welcome and introductions (Marcus Maurer, Germany)
– The importance of HAE management in improving burden of disease and quality of life in patients with HAE (Teresa Caballero, Spain)
– HAE patient and professional support networks (Christine Symons, UK)
– Understanding the role of familial testing in supporting patients with HAE (Konrad Bork, Germany)
– Q & A and closing remarks (All faculty/Chair)

 

17:30 – 19:00 SAT 3 – TEVA Pharmaceuticals Europe B.V., Room 114

From inhalers to IL-5 antibodies: shaping the evolution of asthma management
Chair: Marc Humbert, France

– Welcome and Introduction (Marc Humbert, France)
– Managing the day-to-day challenges of patients with asthma (Dave Singh)
– Meeting the needs of our patients: optimising inhaler use (Sinthia Bosnic-Anticevich, Australia)
– Targeting IL-5: the latest news and views (Guy Brusselle, Belgium)
– Q&A session and close (Marc Humbert, France)

 

17:30 – 19:00 SAT 4 – F. Hoffmann – La Roche AG, Room 115

Severe asthma: unravelling Type 2 pathways
An interactive, intriguing and insightful discussion, exploring the problem of severe asthma and what drives our patients’ disease.

Chair: D.S. Robinson, UK

Introduction: The problem of severe asthma
Chair-led discussion
• What is severe asthma and what is Type 2-driven asthma?
• What are the key pathways involved in Type 2-driven asthma?
• How can we identify these pathways in our patients with severe asthma?
D.S. Robinson, UK, A. Magnan, France, P. Nair, Canada, J. Sastre, Spain

Summary
D.S. Robinson, UK
Q&A

17:30 – 19:00 SAT 5 – DBV Technologies, Room 116

A novel approach in Food Allergy treatment
Chairs: Hugh Sampson, USA and Christophe Dupont, France

– Introduction (Pierre Benhamou, France)
– Epicutaneous Immunotherapy: Mechanism of Action and preclinical data (Lucie Mondoulet, France)
– A Novel Immunotherapy in Food Allergy (Christophe Dupont, France)
– Peanut Epicutaneous Immunotherapy is Effective and Safe to Treat Peanut Allergy: A Multicenter Randomized Controlled Trial (RCT) (VIPES Study) (Hugh Sampson, USA)
– A Promising Therapeutical approach for Eosiniphilic Esophagitis (EoE)  (Jonathan Spergel, USA)

 

MONDAY, 8 JUNE 2015


10:45 – 12:15 CSS 4 – Allergopharma, Room 111

Allergy Diagnosis and Subcutaneous AIT – Today and Tomorrow
Chairs: Moises Calderón, UK and Pascal Demoly, France

– European legislation is threatening in-vivo allergy-diagnostics: what allergen manufacturers can offer allergists (Ludger Klimek, Germany)
– High dose Allergoids – up to date (Beatrice Biló, Italy)
– The potential of subcutaneous AIT (SCIT) (Piotr Kuna, Poland)

 

13:45 – 15:15 CSS 5 – ALK, Hall A

Integrated management of HDM respiratory allergy
Chairs: Jörg Kleine-Tebbe, Germany and Henrik Jacobi, Denmark

– Recap from last year – outcomes from confirmatory clinical trials with the SQ HDM SLIT-tablet in HDM respiratory allergic disease (Jörg Kleine-Tebbe, Germany)
– HDM allergic rhinitis and allergic asthma – are they two sides of the same coin? (Santiago Quirce, Spain)
– Treatment and diagnosis of HDM respiratory allergy – a rhinologist’s perspective (Glenis K. Scadding, UK)
– Treatment and diagnosis of HDM respiratory allergy – a pneumologist’s perspective (J Mark FitzGerald, Canada)
– Do current clinical practice guidelines support an integrated management approach? (Moises Calderón, UK)

 

15:15 – 15:45 PT 3 – CSL Behring, Pro & Con Arena

1500IU in one vial: a new presentation of low-volume, plasma-derived C1 inhibitor concentrate for treatment of acute hereditary angioedema attacks

– Efficacy of body-weight based dose of C1-INH and the new 1500IU presentation – Which patients will benefit? (Markus Magerl, Germany)
– A new 1500IU presentation to optimize patient care – A nurse’s perspective (Stephanie Santucci, Canada)

 

15:45 – 17:15 CSS 6 – Grupo Uriach, Room 111

Matching science and practice in the management of allergic disorders
Chairs: Victoria Cardona, Spain and Jean Bousquet, France

– Consolidated evidence of Rupatadine in the management of Allergic Rhinitis (Joaquim Mullol, Spain)
– Histamine and PAF as therapeutic targets in chronic urticaria (Marcus Maurer, Germany)
– Rupatadine in children with allergic rhinitis or urticaria: unique aspects (F. Estelle R. Simons, Canada)

webcast_button2

 

 

 

17:30 – 19:00 SAT 6 – AstraZeneca, Room 113

Personalizing Medicine for Th2 Obstructive Airway Disease: Phenotypes and the Future
Chair: Thomas Casale, USA

– The Emerging Role of Biomarkers and Diagnostics: Getting the Right Drug to the Right Patient at the Right Time (Leif Bjermer, Sweden)
– Targeted Immune Therapy for Eosinophilic/Th2-Driven Severe Asthma (Thomas Casale, USA)
– Treating COPD Phenotypes in the Era of Biologics (Gerard Criner, USA)

 

17:30 – 19:00 SAT 7 – Nestlé Nutrition Institute, Room 114

Cow’s Milk Protein Allergy: Improving Standards of Care in Pediatric Practice

– Non-IgE CMPA: is it really so rare? (Sibylle Koletzko, Germany)
– Cow’s milk-related symptom score (CoMiSS) for evaluation of milk-related symptoms in young children
(Mikael Kuitunen, Finland)
– Food allergy prevention and modification through introduction of native and modified food proteins
(Anna Novak-Wegrzyn, USA)

 

17:30 – 19:00 SAT 8 – Stallergenes, Room 115

Not all AIT solutions are equal: your choice matters
Chair: Peter Hellings, Belgium

Speakers:
Philippe Moingeon, France
Ralph Mösges, Germany
Ignacio Dàvila, Spain

Interactive case discussions addressing:
– What are the key factors that drive your choice in your allergen extracts selection?
– What’s your treatment strategy for a polyallergic/sensitised patient with respiratory allergy?
– How to engage your patient on the AIT journey?

 

17:30 – 19:00 SAT 9 – GlaxoSmithKline, Room 116

Improving Asthma management requires a multifaceted approach
Chair: Neil Barnes, UK

– Welcome and introduction (Neil Barnes, UK)
– Fluticasone furoate/vilanterol in asthma (David Leather, UK)
– Novel multi dose powder inhaler: designed to address patient’s needs (Raj Sharma, UK)
– Making a difference through a comprehensive approach to patient care (Alvaro Cruz, Brazil)
– Panel discussion chaired by Neil Barnes, UK

 

TUESDAY, 9 JUNE 2015


10:30 – 12:00 CSS 7 – Thermo Fisher, Hall A

Allergen Components and Antibodies – Impact on Patient Management
Chair: Marianne van Hage, Sweden

– Benign versus pathologic allergy – new immunological insights (Patrick G. Holt, Australia)
– The role of components in the diagnosis of food allergy (Hugh Sampson, USA)
– IgE and IgG4 antibodies in peanut allergy – Learnings from the Leap study (Gideon Lack, UK)
– Furry animal allergens, alpha-Gal and red meat – A European perspective (Marianne van Hage, Sweden)

 

12:15 – 13:15 CLS 1 – MEDA Pharma GmbH & Co. KG, Hall A

Beware of Allergy: tackling the problem
Chair: Nikos Papadopoulos, Greece

– Introduction (Nikos Papadopoulos, Greece)
– Beware of Allergy Campaign (Nikos Papadopoulos, Greece)
– Beware rhinitis and asthma (Glenis K. Scadding, UK)
– Beware atopic dermatitis (Thomas Werfel, Germany)
– Beware anaphylaxis (Antonella Muraro, Italy)
– Discussion (Nikos Papadopoulos, Greece)